Clinical trial NCT01110382: A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
Official title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infections
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Abscess, Intra-Abdominal
Abdominal Abscess
Abdomen, Acute
Abdominal Pain
Appendicitis
Rupture
Infection
Intestinal Perforation
Peritonitis
Ileus
Keywords: Anti-Infective Agents
Doripenem
Meropenem
Child, Hospitalized
Complicated Intra-Abdominal Infections
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2010-04-26
Enrollment: 41
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the safety and tolerability of doripenem compared with meropenem in children hospitalized with complicated intra-abdominal infections.

Detailed description: This is a randomized (study drug assigned by chance), double-blind (neither physician nor patient knows the name of the assigned study drugs), double-dummy (all patients are given both a placebo \[salt solution\] and study drug in alternating periods of time during the study), active comparator-controlled (compare the "test" treatment to standard-of-care therapy), multinational, multicenter study to evaluate the safety of the study drugs (doripenem and meropenem) administered by intravenous (iv) infusion (slow injection of drug solution into the vein over a period of time) in children aged 3 months to less than 18 years who are hospitalized with complicated intra abdominal infections (cIAI). Complicated intra abdominal infections include but are not limited to appendicitis with rupture and/or abscess (local collection of pus), acute (severe or intense) gastric, duodenal (beginning section of the small intestine), or gall bladder perforation (a hole in the wall of the stomach, small intestine, or gallbladder), and secondary peritonitis. The study will include 3 periods: a pretreatment (screening) period that will occur within 2 days prior to randomization (assignment of study drug), a treatment period of 5 to 14 days where patients will receive iv study drug treatment only or IV study therapy and a switch to oral antibiotic therapy, and a posttreatment period consisting of 2 study visits. The max duration of study drug therapy is 14 days. The total duration of the study is approximately 7 to 8 weeks. Safety and tolerability will be evaluated by examining the incidence, severity, and type of adverse events, changes in clinical laboratory tests, vital signs measurements, and findings from physical examinations observed during treatment and at each posttreatment visit. An independent monitoring committee (IDMC) will be established for this study to ensure that the safety of patients is not compromised. The IDMC will consist of individuals who are not associated with the conduct of the study, and will include but will not be limited to individuals with expertise relevant to the care of pediatric patients, and including at least one infectious disease physician and at least one statistician. Patients will receive IV Doripenem (20 mg/kg to 500 mg/dose) and meropenem placebo OR meropenem (20 mg/kg to 1 gram/dose) and doripenem placebo once every 8 hours for up to 14 days. If the patient's cIAI symptoms improve after 72 hours of treatment with iv study drug, the investigator may choose to stop iv study drug and switch the patient to an orally administered antibiotic (amoxicillin/clavulanate postassium) to complete the 5- to 14 day course of antibiotic therapy.

Eligibility criteria: Inclusion Criteria:

* Patients who are eligible for the study must have clinical evidence of cIAI
* Require surgical intervention (eg, laparotomy, laparoscopic surgery, or percutaneous drainage) to manage the cIAI
* Require antibacterial therapy for 5 to 14 days in addition to the surgical intervention
* Must, based on the judgment of the investigator, require hospitalization initially and antibacterial therapy for 5 to 14 days in addition to surgical intervention for the treatment of the current cIAI. (Note that the patient must require at least 3 days of IV antibiotic therapy initially)
* Have a signed informed consent form completed by the patient's parent or legal representative (and a signed assent form obtained from patients who are capable of providing assent, typically, children 7 years of age and older)

Exclusion Criteria:

* Have a history of hypersensitivity reactions to carbapenems, cephalosporins, penicillins, or other beta-lactam antibiotics
* concomitant infection including but not limited to suspected or confirmed meningitis or central nervous system infection requiring systemic antibiotic or antifungal therapy in addition to the iv study drug therapy at the time of randomization
* Receipt of nonstudy systemic antibiotic therapy for cIAI for more than 24 hours immediately preceding the start of the infusion of the first dose of iv study drug therapy
* Have a diagnosis of abdominal wall abscess confined to musculature of the abdominal wall, small bowel obstruction or ischemic bowel disease without perforation, traumatic bowel perforation requiring surgery within 12 hours of perforation, or perforation of gastroduodenal ulcers requiring surgery within 24 hours of perforation (these are considered situations of peritoneal soiling before the infection has become established)
* Have simple (noncomplicated), nonperforated appendicitis or gangrenous appendicitis without rupture into the peritoneal cavity identified during a surgical procedure OR presence of spontaneous bacterial peritonitis or peritonitis associated with cirrhosis or chronic ascites
* Known at the time of randomization to have a cIAI caused by at least one pathogen that is nonsusceptible to doripenem or meropenem
* Presence of any of the following clinically significant laboratory abnormalities: Hematocrit of less than 20%, absolute neutrophil count (ANC) \<500 cells/µL, platelet count \<40,000 cells/µL, serum alanine aminotransferase or aspartate aminotransferase (AST) or total bilirubin 5 times or greater the age-specific upper limit of normal (ULN) or acute/chronic renal insufficiency with a baseline creatinine clearance \<50 mL per minute or requires dialysis therapy for any reason
* Have a history of uncontrolled epilepsy defined as at least 1 seizure within the 6 months before randomization

Primary outcomes:
measure: The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit
timeFrame: TOC (7 to 14 days after the last dose of study medication therapy)
Secondary outcomes:
measure: The Number of Participants With Clinical Improvement Rate at End of IV (EIV) Visit
timeFrame: EIV (within 24 hours after completion of the last dose of IV study medication therapy)
measure: The Number of Participants With Clinical Cure Rate at Late Follow-Up (LFU) Visit
timeFrame: LFU (28 to 42 days after the last dose of study medication therapy)
measure: The Number of Participants With Favorable Per-participant Microbiological Response
timeFrame: EIV (within 24 hours after completion of the last dose of IV study medication therapy), TOC (7 to 14 days after the last dose of study medication therapy), and LFU (28 to 42 days after the last dose of study medication therapy)
measure: Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at End of IV (EIV) Visit
timeFrame: EIV (within 24 hours after completion of the last dose of IV study medication therapy)
measure: Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Test Of Cure (TOC) Visit
timeFrame: TOC (7 to 14 days after the last dose of study medication therapy)
measure: Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Late Follow-Up (LFU) Visit
timeFrame: LFU (28 to 42 days after the last dose of study medication therapy)
Other outcomes:
Locations:
city: San Diego
country: United States
state: California
city: Washington
country: United States
state: District of Columbia
city: Cleveland
country: United States
state: Ohio
city: Toledo
country: United States
state: Ohio
city: Buenos Aires
country: Argentina
city: Córdoba
country: Argentina
city: Loma Hermosa N/A
country: Argentina
city: Paraná, Entre Ríos
country: Argentina
city: Santa Fe
country: Argentina
city: Passo Fundo
country: Brazil
city: São Paulo
country: Brazil
city: Santiago
country: Chile
city: Valdivia X Región
country: Chile
city: Bogota
country: Colombia
city: Floridablanca
country: Colombia
city: Riga
country: Latvia
city: Kaunas
country: Lithuania
city: Vilnius
country: Lithuania
city: Zona
country: Panama
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC C. Clinical Trial
role: STUDY_DIRECTOR
References: